Akorn Offers Update on Recent Product Lines: Unveils AP-Rated Generic of Astella's Adenoscan, Hospira's Precedex Injection, AbbVie's Marinol Caps, Re-Launching Sulfamethoxazole, Trimethoprim

Akorn, Inc.

, a leading specialty pharmaceutical company, today announced several generic product launches that build on Akorn's commitment to serve the company's specialty generic customers and patients. Adenosine Injection. Akorn launched Adenosine Injection, USP, 60 mg/20 mL in 20 mL vials and 90 mg/30mL in 30mL vials, on December 22, 2014. Akorn's product is an AP-rated generic version of Astellas' Adenoscan^® Injection and is a pharmacologic stress agent indicated as an adjunct to thallium-201 myocardial perfusion scintigraphy in patients unable to exercise adequately. According to IMS Heath, sales of branded and generic versions of Adenosine Injection, USP, 60 mg/20 mL in 20 mL vials and 90 mg/30mL in 30mL vials were approximately $33 million for the 12 months ended January 31, 2015. Dexmedetomidine Hydrochloride Injection. Akorn launched Dexmedetomidine Hydrochloride Injection, 200mcg/2mL single dose vials on March 3, 2015. Akorn's product is an AP-rated generic version of Hospira's Precedex™ Injection. Akorn's Dexmedetomidine Hydrochloride Injection is a relatively selective alpha[2]-andrenergic agonist indicated for the sedation of non-intubated patients prior to and/or during surgical and other procedures. According to IMS Heath, sales of branded and generic versions of Dexmedetomidine Hydrochloride Injection were approximately $121 million for the 12 months ended January 31, 2015. Dronabinol Capsules. Akorn launched Dronabinol Capsules, USP CIII in 2.5 mg, 5 mg and 10 mg strengths on February 2, 2015. Akorn's product is an AB-rated version of Abbvie's Marinol^® Capsules and are indicated for the treatment of nausea and vomiting associated with cancer chemotherapy in patients who have failed to respond adequately to conventional antiemetic treatments. According to IMS Health, sales of branded and generic versions of Dronabinol Capsules were approximately $132 million for the 12 months ended January 31, 2015. Sulfamethoxazole and Trimethoprim Oral Suspension. Akorn re-launched Sulfamethoxazole and Trimethoprim Oral Suspension (SMZ), USP 200 mg/40 mg per 5 mL in cherry- and grape-flavored oral suspensions on December 15, 2014. Akorn's product is an antibacterial combination product indicated to treat bacterial infections resulting in urinary tract infections, acute otitis media, acute exacerbations of chronic bronchitis in adults, Shigellosis, Pneumocystis jiroveci Pneumonia and traveler's diarrhea in adults. According to IMS Health, sales of SMZ were approximately $56 million for the 12 months ended January 31, 2015.